Literature DB >> 30370226

Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts.

Kristopher A Lyon1,2, Jason H Huang1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30370226      PMCID： PMC6202032          DOI： 10.21037/tcr.2018.08.19

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  23 in total

1.  Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years.

Authors:  Ken-Ichiro Matsuda; Kaori Sakurada; Kenji Nemoto; Takamasa Kayama; Yukihiko Sonoda
Journal:  Int J Clin Oncol       Date:  2018-05-23       Impact factor: 3.402

2.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

3.  Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Authors:  Jaime Gállego Pérez-Larraya; François Ducray; Olivier Chinot; Isabelle Catry-Thomas; Luc Taillandier; Jean-Sébastien Guillamo; Chantal Campello; Annick Monjour; Stéphanie Cartalat-Carel; Maryline Barrie; Aymeri Huchet; Patrick Beauchesne; Mona Matta; Karima Mokhtari; Marie-Laure Tanguy; Jérôme Honnorat; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

4.  The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?

Authors:  D T Blumenthal; L Mendel; F Bokstein
Journal:  J Neurooncol       Date:  2015-12-31       Impact factor: 4.130

5.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

7.  Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.

Authors:  Ranjith Babu; Jordan M Komisarow; Vijay J Agarwal; Shervin Rahimpour; Akshita Iyer; Dylan Britt; Isaac O Karikari; Peter M Grossi; Steven Thomas; Allan H Friedman; Cory Adamson
Journal:  J Neurosurg       Date:  2015-10-09       Impact factor: 5.115

8.  Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.

Authors:  H-G Wirsching; G Tabatabai; U Roelcke; A F Hottinger; F Jörger; A Schmid; L Plasswilm; D Schrimpf; C Mancao; D Capper; K Conen; T Hundsberger; F Caparrotti; R von Moos; C Riklin; J Felsberg; P Roth; D T W Jones; S Pfister; E J Rushing; L Abrey; G Reifenberger; L Held; A von Deimling; A Ochsenbein; M Weller
Journal:  Ann Oncol       Date:  2018-06-01       Impact factor: 32.976

9.  Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.

Authors:  Olivier L Chinot; Ryo Nishikawa; Warren Mason; Roger Henriksson; Frank Saran; Timothy Cloughesy; Josep Garcia; Cedric Revil; Lauren Abrey; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2016-03-22       Impact factor: 12.300

10.  Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Authors:  Germán Reyes-Botero; Stéphanie Cartalat-Carel; Olivier L Chinot; Maryline Barrie; Luc Taillandier; Patrick Beauchesne; Isabelle Catry-Thomas; Jérôme Barrière; Jean-Sebastien Guillamo; Michel Fabbro; Didier Frappaz; Alexandra Benouaich-Amiel; Emilie Le Rhun; Chantal Campello; Isabelle Tennevet; François Ghiringhelli; Marie-Laure Tanguy; Karima Mokhtari; Jérôme Honnorat; Jean-Yves Delattre
Journal:  Oncologist       Date:  2018-02-22
View more
  5 in total

Review 1.  Role of the Pro-Inflammatory Tumor Microenvironment in Extracellular Vesicle-Mediated Transfer of Therapy Resistance.

Authors:  Layla Simón; Sofía Sanhueza; Belén Gaete-Ramírez; Manuel Varas-Godoy; Andrew F G Quest
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

Review 2.  Looking for the Holy Grail-Drug Candidates for Glioblastoma Multiforme Chemotherapy.

Authors:  Beata Pająk
Journal:  Biomedicines       Date:  2022-04-26

3.  Demethoxycurcumin analogue DMC-BH inhibits orthotopic growth of glioma stem cells by targeting JNK/ERK signaling.

Authors:  Lei Shi; Guan Sun; Haifeng Zhu
Journal:  Aging (Albany NY)       Date:  2020-07-24       Impact factor: 5.682

4.  Application of Intravoxel Incoherent Motion Diffusion-Weighted Imaging in Predicting and Monitoring Early Efficacy of Anti-Angiogenic Therapy in the C6 Glioma Rat Model.

Authors:  Weishu Hou; Yangyang Xue; Yinfeng Qian; Hongli Pan; Man Xu; Yujun Shen; Xiaohu Li; Yongqiang Yu
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

5.  Targeting TRAF3IP2 inhibits angiogenesis in glioblastoma.

Authors:  Amin Izadpanah; Fatemeh Daneshimehr; Kurtis Willingham; Zahra Barabadi; Stephen E Braun; Aaron Dumont; Ricardo Mostany; Bysani Chandrasekar; Eckhard U Alt; Reza Izadpanah
Journal:  Front Oncol       Date:  2022-08-15       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.